Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
172.20
+0.02 (+0.01%)
5:23:00 PM EDT: $172.53 +0.33 (+0.19%)
Products

FDA Says Reports Of Adverse Events After Janssen Covid-19 Vaccine Use Under Eua Suggest Increased Risk Of Guillain-Barré Syndrome In 42 Days After Vaccination

Published: 07/12/2021 21:12 GMT
Johnson & Johnson (JNJ) - FDA Says Reports of Adverse Events After Janssen Covid-19 Vaccine Use Under Eua Suggest Increased Risk of Guillain-barrÉ Syndrome in 42 Days After Vaccination.
FDA Says Granted Janssen's Request After Reviewing Changes & Data to Support Revisions to Eua Fact Sheets, Changes to Include Information About Guillain-barrÉ Syndrome.